Volpara inks deal with Microsoft, how will its shares react?
Digital health solutions developer, Volpara Health Technologies Limited $Volpara Health Technologies Ltd(VHT.AU$ shared today that it has joined hands with Microsoft $Microsoft(MSFT.US$ to speed up the research and development of the products that detect breast arterial calcification (BAC), which is associated with heart disease or a high risk of cardiovascular disease.
The shares were performing in line with the ASX 200 healthcare index (XHJ), which was down 0.977% at the same time. In the last five trading sessions, the shares tumbled 23%, and in one month, shares dropped 36%. On a year-to-date basis, the share price sank by 57%.
Microsoft has a great advantage in the field of Artificial Intelligence and computing services. The product to be developed under the collaboration will use AI and mammograms and capitalise upon the recent BAC patent granted to Volpara. Microsoft’s machine learning and AI specialists would support improving the BACs model along with data processing.
Microsoft and Volpara, together, will be working towards bettering women’s health through science and innovation, VHT release stated. The BACs product would help radiologists identify the need to take steps to prevent heart disease. It would work as a cardiac decision-support tool and mark the entry of Volpara into a new area of care.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
